🚀 VC round data is live in beta, check it out!
Samsung Bioepis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Samsung Bioepis and similar public comparables like Baxter International, Mankind Pharma, Madrigal Pharmaceuticals, Wuxi XDC and more.
Samsung Bioepis Overview
About Samsung Bioepis
Samsung Epis Holdings Co Ltd is engaged in managing and making new investments in the biopharmaceutical sector.
Founded
2025
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$10B
Samsung Bioepis Financials
Samsung Bioepis reported last 12-month revenue of $1B and EBITDA of $310M.
In the same LTM period, Samsung Bioepis generated $707M in gross profit, $310M in EBITDA, and $272M in net income.
Revenue (LTM)
Samsung Bioepis P&L
In the most recent fiscal year, Samsung Bioepis reported revenue of — and net income of —.
Samsung Bioepis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | — | XXX | XXX | XXX |
| Gross Profit | $707M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | — | XXX | XXX | XXX |
| EBITDA | $310M | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | — | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | — | XXX | XXX | XXX |
| Net Profit | $272M | XXX | — | XXX | XXX | XXX |
| Net Margin | 23% | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Samsung Bioepis Stock Performance
Samsung Bioepis has current market cap of $10B, and enterprise value of $10B.
Market Cap Evolution
Samsung Bioepis' stock price is $411.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $10B | — | XXX | XXX | XXX | — |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSamsung Bioepis Valuation Multiples
Samsung Bioepis trades at 8.8x EV/Revenue multiple, and 33.0x EV/EBITDA.
EV / Revenue (LTM)
Samsung Bioepis Financial Valuation Multiples
As of March 28, 2026, Samsung Bioepis has market cap of $10B and EV of $10B.
Equity research analysts estimate Samsung Bioepis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Samsung Bioepis has a P/E ratio of 37.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 8.8x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | 33.0x | XXX | — | XXX | XXX | XXX |
| EV/EBIT | 38.9x | XXX | — | XXX | XXX | XXX |
| EV/Gross Profit | 14.5x | XXX | — | XXX | XXX | XXX |
| P/E | 37.7x | XXX | — | XXX | XXX | XXX |
| EV/FCF | 73.8x | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Samsung Bioepis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Samsung Bioepis Margins & Growth Rates
Samsung Bioepis' revenue in the last 12 month grew by 6%.
Samsung Bioepis' rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Samsung Bioepis' rule of X is 42% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Samsung Bioepis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | — | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | — | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 42% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Samsung Bioepis Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Baxter International | XXX | XXX | XXX | XXX | XXX | XXX |
| Mankind Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Madrigal Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Wuxi XDC | XXX | XXX | XXX | XXX | XXX | XXX |
| Samchundang Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Samsung Bioepis M&A Activity
Samsung Bioepis acquired XXX companies to date.
Last acquisition by Samsung Bioepis was on XXXXXXXX, XXXXX. Samsung Bioepis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Samsung Bioepis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSamsung Bioepis Investment Activity
Samsung Bioepis invested in XXX companies to date.
Samsung Bioepis made its latest investment on XXXXXXXX, XXXXX. Samsung Bioepis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Samsung Bioepis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Samsung Bioepis
| When was Samsung Bioepis founded? | Samsung Bioepis was founded in 2025. |
| Where is Samsung Bioepis headquartered? | Samsung Bioepis is headquartered in South Korea. |
| Is Samsung Bioepis publicly listed? | Yes, Samsung Bioepis is a public company listed on Korea Exchange. |
| What is the stock symbol of Samsung Bioepis? | Samsung Bioepis trades under 0126Z0 ticker. |
| When did Samsung Bioepis go public? | Samsung Bioepis went public in 2025. |
| Who are competitors of Samsung Bioepis? | Samsung Bioepis main competitors are Baxter International, Mankind Pharma, Madrigal Pharmaceuticals, Wuxi XDC. |
| What is the current market cap of Samsung Bioepis? | Samsung Bioepis' current market cap is $10B. |
| What is the current revenue of Samsung Bioepis? | Samsung Bioepis' last 12 months revenue is $1B. |
| What is the current revenue growth of Samsung Bioepis? | Samsung Bioepis revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Samsung Bioepis? | Current revenue multiple of Samsung Bioepis is 8.8x. |
| Is Samsung Bioepis profitable? | Yes, Samsung Bioepis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Samsung Bioepis? | Samsung Bioepis' last 12 months EBITDA is $310M. |
| What is Samsung Bioepis' EBITDA margin? | Samsung Bioepis' last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Samsung Bioepis? | Current EBITDA multiple of Samsung Bioepis is 33.0x. |
| What is the current FCF of Samsung Bioepis? | Samsung Bioepis' last 12 months FCF is $139M. |
| What is Samsung Bioepis' FCF margin? | Samsung Bioepis' last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Samsung Bioepis? | Current FCF multiple of Samsung Bioepis is 73.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.